The Experts below are selected from a list of 19422 Experts worldwide ranked by ideXlab platform
P E Keck - One of the best experts on this subject based on the ideXlab platform.
-
Olanzapine versus haloperidol in Schizoaffective Disorder, bipolar type.
Journal of Affective Disorders, 2001Co-Authors: M Tohen, F Zhang, P E Keck, P D Feldman, R C Risser, P V Tran, A BreierAbstract:Abstract Background: The present analysis was performed on data from a subsample of patients with Schizoaffective Disorder, bipolar type, who participated in a multicenter, double-blind study comparing olanzapine to haloperidol. Methods: Patients with Schizoaffective Disorder bipolar type, characterized as currently manic, mixed, depressed, or euthymic, were assessed weekly for 6 weeks during treatment with either olanzapine or haloperidol. Manic symptoms were measured using the sum of six items of the BPRS, and depressive symptoms were assessed using the Montgomery–Asberg Depression Rating Scale. In addition, cognitive functioning was measured using the sum of seven items from the PANSS. Repeated measures analyses were performed using random coefficients regression of the serial measurement of manic, cognitive, and depressive symptoms. Results: A significant treatment difference was detected overall, indicating that olanzapine was significantly more effective than haloperidol in reducing symptoms of depression and improving patients’ cognitive symptoms. The superiority of olanzapine over haloperidol in the reduction of manic symptoms did not reach statistical significance ( P =.052). The greatest improvement in both manic and cognitive symptoms was seen in the olanzapine-treated ‘currently manic’ subgroup, and least improvement in the haloperidol-treated ‘euthymic’ subgroup. Depressive symptoms were most improved in the olanzapine-treated ‘depressed’ subgroup, and least improved in the corresponding haloperidol subgroup. Conclusions: Overall, olanzapine was superior to haloperidol with respect to thymoleptic effects in patients with Schizoaffective Disorder, bipolar type.
-
Olanzapine versus haloperidol in Schizoaffective Disorder, bipolar type.
Journal of affective disorders, 2001Co-Authors: M Tohen, F Zhang, P E Keck, P D Feldman, R C Risser, P V Tran, A BreierAbstract:The present analysis was performed on data from a subsample of patients with Schizoaffective Disorder, bipolar type, who participated in a multicenter, double-blind study comparing olanzapine to haloperidol. Patients with Schizoaffective Disorder bipolar type, characterized as currently manic, mixed, depressed, or euthymic, were assessed weekly for 6 weeks during treatment with either olanzapine or haloperidol. Manic symptoms were measured using the sum of six items of the BPRS, and depressive symptoms were assessed using the Montgomery-Asberg Depression Rating Scale. In addition, cognitive functioning was measured using the sum of seven items from the PANSS. Repeated measures analyses were performed using random coefficients regression of the serial measurement of manic, cognitive, and depressive symptoms. A significant treatment difference was detected overall, indicating that olanzapine was significantly more effective than haloperidol in reducing symptoms of depression and improving patients' cognitive symptoms. The superiority of olanzapine over haloperidol in the reduction of manic symptoms did not reach statistical significance (P=.052). The greatest improvement in both manic and cognitive symptoms was seen in the olanzapine-treated 'currently manic' subgroup, and least improvement in the haloperidol-treated 'euthymic' subgroup. Depressive symptoms were most improved in the olanzapine-treated 'depressed' subgroup, and least improved in the corresponding haloperidol subgroup. Overall, olanzapine was superior to haloperidol with respect to thymoleptic effects in patients with Schizoaffective Disorder, bipolar type.
-
An overview of the treatment of Schizoaffective Disorder.
The Journal of clinical psychiatry, 1999Co-Authors: S L Mcelroy, P E Keck, Stephan M. StrakowskiAbstract:Schizoaffective Disorder is a common, chronic, and frequently disabling psychiatric Disorder. However, its pharmacologic treatment has not been well studied. The authors review studies of traditional and novel pharmacologic agents in treatment of Schizoaffective Disorder, and based on the findings, present preliminary pharmacologic treatment guidelines for the Disorder.
-
An overview of the treatment of Schizoaffective Disorder. Discussion
1999Co-Authors: S L Mcelroy, P E Keck, Stephen M. Strakowski, Shelton, Bowden, Kane, TohenAbstract:Schizoaffective Disorder is a common, chronic, and frequently disabling psychiatric Disorder. However, its pharmacologic treatment has not been well studied. The authors review studies of traditional and novel pharmacologic agents in treatment of Schizoaffective Disorder, and based on the findings, present preliminary pharmacologic treatment guidelines for the Disorder.
-
New developments in the pharmacologic treatment of Schizoaffective Disorder.
The Journal of clinical psychiatry, 1996Co-Authors: P E Keck, Susan L. Mcelroy, Stephen M. StrakowskiAbstract:Schizoaffective Disorder is a common, chronic, and frequently disabling psychiatric Disorder. However, the pharmacologic treatment of this Disorder has not been well studied. The authors reviewed the available literature regarding the acute and prophylactic pharmacologic treatment of Schizoaffective Disorder Fourteen controlled studies, and only 10 using modern criteria to define the Disorder, reported on the efficacy of typical antipsychotics, thymoleptics, or the combination in the acute treatment of Schizoaffective Disorder. In acute treatment studies of Schizoaffective Disorder, bipolar type (manic), typical antipsychotics and lithium were comparable in efficacy except in agitated patients for whom antipsychotics were superior. The combination of lithium and antipsychotics appeared to be superior to antipsychotics alone in this patient subtype. In the only controlled study of the acute treatment of Schizoaffective Disorder, depressive type, combined treatment with antipsychotics and antidepressants was not superior to treatment with antipsychotics alone. Although combination treatment with antipsychotics and thymoleptics is common practice in the prophylactic management of Schizoaffective Disorder, the efficacy of this strategy has not been studied in controlled trials. Recent preliminary data from open trials suggest that the mood stabilizers valproate and carbamazepine and the novel antipsychotics clozapine and risperidone may be promising new treatments for Schizoaffective Disorder. Evidence implicating 5-HT2 receptor blockade as an important mechanism underlying possible thymoleptic activity for clozapine and risperidone is also reviewed.
Susan L. Mcelroy - One of the best experts on this subject based on the ideXlab platform.
-
Schizoaffective Disorder: role of atypical antipsychotics
Schizophrenia Research, 1999Co-Authors: Paul E. Keck, Susan L. Mcelroy, Stephan M. StrakowskiAbstract:The pharmacologic treatment of Schizoaffective Disorder is one of the least well-studied areas of contemporary pharmacotherapy. The authors review available literature on the traditional pharmacologic treatment of Schizoaffective Disorder, new data on the atypical antipsychotics, and potential pharmacologic mechanisms by which these new agents may produce thymoleptic activity.
-
New developments in the pharmacologic treatment of Schizoaffective Disorder.
The Journal of clinical psychiatry, 1996Co-Authors: Paul E. Keck, Susan L. Mcelroy, Stephen M. StrakowskiAbstract:Background : Schizoaffective Disorder is a common, chronic, and frequently disabling psychiatric Disorder. However, the pharmacologic treatment of this Disorder has not been well studied. Method : The authors reviewed the available literature regarding the acute and prophylactic pharmacologic treatment of Schizoaffective Disorder. Results : Fourteen controlled studies, and only 10 using modern criteria to define the Disorder, reported on the efficacy of typical antipsychotics, thymoleptics, or the combination in the acute treatment of Schizoaffective Disorder. In acute treatment studies of Schizoaffective Disorder, bipolar type (manic), typical antipsychotics and lithium were comparable in efficacy except in agitated patients for whom antipsychotics were superior. The combination of lithium and antipsychotics appeared to be superior to antipsychotics alone in this patient subtype. In the only controlled study of the acute treatment of Schizoaffective Disorder, depressive type, combined treatment with antipsychotics and antidepressants was not superior to treatment with antipsychotics alone. Conclusion: Although combination treatment with antipsychotics and thymoleptics is common practice in the prophylactic management of Schizoaffective Disorder, the efficacy of this strategy has not been studied in controlled trials. Recent preliminary data from open trials suggest that the mood stabilizers valproate and carbamazepine and the novel antipsychotics clozapine and risperidone may be promising new treatments for Schizoaffective Disorder. Evidence implicating 5-HT 2 receptor blockade as an important mechanism underlying possible thymoleptic activity for clozapine and risperidone is also reviewed.
-
New developments in the pharmacologic treatment of Schizoaffective Disorder.
The Journal of clinical psychiatry, 1996Co-Authors: P E Keck, Susan L. Mcelroy, Stephen M. StrakowskiAbstract:Schizoaffective Disorder is a common, chronic, and frequently disabling psychiatric Disorder. However, the pharmacologic treatment of this Disorder has not been well studied. The authors reviewed the available literature regarding the acute and prophylactic pharmacologic treatment of Schizoaffective Disorder Fourteen controlled studies, and only 10 using modern criteria to define the Disorder, reported on the efficacy of typical antipsychotics, thymoleptics, or the combination in the acute treatment of Schizoaffective Disorder. In acute treatment studies of Schizoaffective Disorder, bipolar type (manic), typical antipsychotics and lithium were comparable in efficacy except in agitated patients for whom antipsychotics were superior. The combination of lithium and antipsychotics appeared to be superior to antipsychotics alone in this patient subtype. In the only controlled study of the acute treatment of Schizoaffective Disorder, depressive type, combined treatment with antipsychotics and antidepressants was not superior to treatment with antipsychotics alone. Although combination treatment with antipsychotics and thymoleptics is common practice in the prophylactic management of Schizoaffective Disorder, the efficacy of this strategy has not been studied in controlled trials. Recent preliminary data from open trials suggest that the mood stabilizers valproate and carbamazepine and the novel antipsychotics clozapine and risperidone may be promising new treatments for Schizoaffective Disorder. Evidence implicating 5-HT2 receptor blockade as an important mechanism underlying possible thymoleptic activity for clozapine and risperidone is also reviewed.
-
Pharmacologic treatment of Schizoaffective Disorder
Psychopharmacology, 1994Co-Authors: Paul E. Keck, Susan L. Mcelroy, Stephen M. Strakowski, Scott A. WestAbstract:In contrast to the considerable systematic study of the pharmacologic treatment of schizophrenia and mood Disorders, the pharmacologic treatment of Schizoaffective Disorder has been relatively ignored. The authors reviewed the available literature regarding the pharmacologic treatment of Schizoaffective Disorder. The total number of controlled studies of the acute and prophylactic treatment of Schizoaffective Disorder was small and few used modern criteria to define the Disorder. In studies of Schizoaffective Disorder, bipolar type (manic), lithium and antipsychotics produced comparable albeit incomplete responses, except in highly agitated patients when antipsychotics exerted superior efficacy. The combination of lithium and antipsychotics appeared to be superior to antipsychotics alone for Schizoaffective, bipolar type patients. In the only controlled study of Schizoaffective Disorder, depressed type, the presumed superiority of combined antidepressant and antipsychotic treatment to antipsychotic alone was not found. Although combined antipsychotic and thymoleptic treatment represents common prophylactic management of Schizoaffective Disorder in clinical practice, the efficacy of this strategy has not been studied in controlled trials. Advances in the nosology of Schizoaffective Disorder, emerging epidemiologic data demonstrating large numbers of patients with this Disorder in clinical populations, and preliminary evidence that clozapine may have combined antipsychotic and thymoleptic properties as well as efficacy in both the psychotic and affective components of Schizoaffective Disorder, suggest that renewed interest in the diagnosis and treatment of this Disorder may lead to improved delivery of care for this understudied but seriously ill group of patients.
-
Clozapine in the treatment of psychotic mood Disorders, Schizoaffective Disorder, and schizophrenia.
The Journal of clinical psychiatry, 1991Co-Authors: Susan L. Mcelroy, Paul E. Keck, Harrison G. Pope, Jonathan O. Cole, F. R. Frankenberg, Harlyn G. Aizley, S. O'brienAbstract:Background Although growing research indicates that the atypical antipsychotic agent clozapine is effective in patients with schizophrenia, little is known about the efficacy of clozapine in patients with Schizoaffective Disorder or psychotic mood Disorders. The purpose of this study was to assess whether or not clozapine is effective in some patients with Schizoaffective Disorder or psychotic mood Disorders. Method By surveying treating clinicians and chart data, we assessed treatment response in 85 consecutive patients, including 39 with schizophrenia, 25 with Schizoaffective Disorder, and 14 with bipolar Disorder with psychotic features, who received clozapine for at least 6 weeks at our center. Results All patients were either inadequately responsive to or unable to tolerate standard somatic therapies. Compared to patients with schizophrenia, patients with Schizoaffective Disorder and bipolar Disorder with psychotic features displayed significantly higher response rates to clozapine. Conclusion Clozapine may be a useful drug in the treatment of patients with Schizoaffective Disorder or psychotic mood Disorders who are treatment resistant or intolerant of side effects.
Paul E. Keck - One of the best experts on this subject based on the ideXlab platform.
-
Schizoaffective Disorder: role of atypical antipsychotics
Schizophrenia Research, 1999Co-Authors: Paul E. Keck, Susan L. Mcelroy, Stephan M. StrakowskiAbstract:The pharmacologic treatment of Schizoaffective Disorder is one of the least well-studied areas of contemporary pharmacotherapy. The authors review available literature on the traditional pharmacologic treatment of Schizoaffective Disorder, new data on the atypical antipsychotics, and potential pharmacologic mechanisms by which these new agents may produce thymoleptic activity.
-
New developments in the pharmacologic treatment of Schizoaffective Disorder.
The Journal of clinical psychiatry, 1996Co-Authors: Paul E. Keck, Susan L. Mcelroy, Stephen M. StrakowskiAbstract:Background : Schizoaffective Disorder is a common, chronic, and frequently disabling psychiatric Disorder. However, the pharmacologic treatment of this Disorder has not been well studied. Method : The authors reviewed the available literature regarding the acute and prophylactic pharmacologic treatment of Schizoaffective Disorder. Results : Fourteen controlled studies, and only 10 using modern criteria to define the Disorder, reported on the efficacy of typical antipsychotics, thymoleptics, or the combination in the acute treatment of Schizoaffective Disorder. In acute treatment studies of Schizoaffective Disorder, bipolar type (manic), typical antipsychotics and lithium were comparable in efficacy except in agitated patients for whom antipsychotics were superior. The combination of lithium and antipsychotics appeared to be superior to antipsychotics alone in this patient subtype. In the only controlled study of the acute treatment of Schizoaffective Disorder, depressive type, combined treatment with antipsychotics and antidepressants was not superior to treatment with antipsychotics alone. Conclusion: Although combination treatment with antipsychotics and thymoleptics is common practice in the prophylactic management of Schizoaffective Disorder, the efficacy of this strategy has not been studied in controlled trials. Recent preliminary data from open trials suggest that the mood stabilizers valproate and carbamazepine and the novel antipsychotics clozapine and risperidone may be promising new treatments for Schizoaffective Disorder. Evidence implicating 5-HT 2 receptor blockade as an important mechanism underlying possible thymoleptic activity for clozapine and risperidone is also reviewed.
-
Pharmacologic treatment of Schizoaffective Disorder
Psychopharmacology, 1994Co-Authors: Paul E. Keck, Susan L. Mcelroy, Stephen M. Strakowski, Scott A. WestAbstract:In contrast to the considerable systematic study of the pharmacologic treatment of schizophrenia and mood Disorders, the pharmacologic treatment of Schizoaffective Disorder has been relatively ignored. The authors reviewed the available literature regarding the pharmacologic treatment of Schizoaffective Disorder. The total number of controlled studies of the acute and prophylactic treatment of Schizoaffective Disorder was small and few used modern criteria to define the Disorder. In studies of Schizoaffective Disorder, bipolar type (manic), lithium and antipsychotics produced comparable albeit incomplete responses, except in highly agitated patients when antipsychotics exerted superior efficacy. The combination of lithium and antipsychotics appeared to be superior to antipsychotics alone for Schizoaffective, bipolar type patients. In the only controlled study of Schizoaffective Disorder, depressed type, the presumed superiority of combined antidepressant and antipsychotic treatment to antipsychotic alone was not found. Although combined antipsychotic and thymoleptic treatment represents common prophylactic management of Schizoaffective Disorder in clinical practice, the efficacy of this strategy has not been studied in controlled trials. Advances in the nosology of Schizoaffective Disorder, emerging epidemiologic data demonstrating large numbers of patients with this Disorder in clinical populations, and preliminary evidence that clozapine may have combined antipsychotic and thymoleptic properties as well as efficacy in both the psychotic and affective components of Schizoaffective Disorder, suggest that renewed interest in the diagnosis and treatment of this Disorder may lead to improved delivery of care for this understudied but seriously ill group of patients.
-
Clozapine in the treatment of psychotic mood Disorders, Schizoaffective Disorder, and schizophrenia.
The Journal of clinical psychiatry, 1991Co-Authors: Susan L. Mcelroy, Paul E. Keck, Harrison G. Pope, Jonathan O. Cole, F. R. Frankenberg, Harlyn G. Aizley, S. O'brienAbstract:Background Although growing research indicates that the atypical antipsychotic agent clozapine is effective in patients with schizophrenia, little is known about the efficacy of clozapine in patients with Schizoaffective Disorder or psychotic mood Disorders. The purpose of this study was to assess whether or not clozapine is effective in some patients with Schizoaffective Disorder or psychotic mood Disorders. Method By surveying treating clinicians and chart data, we assessed treatment response in 85 consecutive patients, including 39 with schizophrenia, 25 with Schizoaffective Disorder, and 14 with bipolar Disorder with psychotic features, who received clozapine for at least 6 weeks at our center. Results All patients were either inadequately responsive to or unable to tolerate standard somatic therapies. Compared to patients with schizophrenia, patients with Schizoaffective Disorder and bipolar Disorder with psychotic features displayed significantly higher response rates to clozapine. Conclusion Clozapine may be a useful drug in the treatment of patients with Schizoaffective Disorder or psychotic mood Disorders who are treatment resistant or intolerant of side effects.
A Breier - One of the best experts on this subject based on the ideXlab platform.
-
Olanzapine versus haloperidol in Schizoaffective Disorder, bipolar type.
Journal of Affective Disorders, 2001Co-Authors: M Tohen, F Zhang, P E Keck, P D Feldman, R C Risser, P V Tran, A BreierAbstract:Abstract Background: The present analysis was performed on data from a subsample of patients with Schizoaffective Disorder, bipolar type, who participated in a multicenter, double-blind study comparing olanzapine to haloperidol. Methods: Patients with Schizoaffective Disorder bipolar type, characterized as currently manic, mixed, depressed, or euthymic, were assessed weekly for 6 weeks during treatment with either olanzapine or haloperidol. Manic symptoms were measured using the sum of six items of the BPRS, and depressive symptoms were assessed using the Montgomery–Asberg Depression Rating Scale. In addition, cognitive functioning was measured using the sum of seven items from the PANSS. Repeated measures analyses were performed using random coefficients regression of the serial measurement of manic, cognitive, and depressive symptoms. Results: A significant treatment difference was detected overall, indicating that olanzapine was significantly more effective than haloperidol in reducing symptoms of depression and improving patients’ cognitive symptoms. The superiority of olanzapine over haloperidol in the reduction of manic symptoms did not reach statistical significance ( P =.052). The greatest improvement in both manic and cognitive symptoms was seen in the olanzapine-treated ‘currently manic’ subgroup, and least improvement in the haloperidol-treated ‘euthymic’ subgroup. Depressive symptoms were most improved in the olanzapine-treated ‘depressed’ subgroup, and least improved in the corresponding haloperidol subgroup. Conclusions: Overall, olanzapine was superior to haloperidol with respect to thymoleptic effects in patients with Schizoaffective Disorder, bipolar type.
-
Olanzapine versus haloperidol in Schizoaffective Disorder, bipolar type.
Journal of affective disorders, 2001Co-Authors: M Tohen, F Zhang, P E Keck, P D Feldman, R C Risser, P V Tran, A BreierAbstract:The present analysis was performed on data from a subsample of patients with Schizoaffective Disorder, bipolar type, who participated in a multicenter, double-blind study comparing olanzapine to haloperidol. Patients with Schizoaffective Disorder bipolar type, characterized as currently manic, mixed, depressed, or euthymic, were assessed weekly for 6 weeks during treatment with either olanzapine or haloperidol. Manic symptoms were measured using the sum of six items of the BPRS, and depressive symptoms were assessed using the Montgomery-Asberg Depression Rating Scale. In addition, cognitive functioning was measured using the sum of seven items from the PANSS. Repeated measures analyses were performed using random coefficients regression of the serial measurement of manic, cognitive, and depressive symptoms. A significant treatment difference was detected overall, indicating that olanzapine was significantly more effective than haloperidol in reducing symptoms of depression and improving patients' cognitive symptoms. The superiority of olanzapine over haloperidol in the reduction of manic symptoms did not reach statistical significance (P=.052). The greatest improvement in both manic and cognitive symptoms was seen in the olanzapine-treated 'currently manic' subgroup, and least improvement in the haloperidol-treated 'euthymic' subgroup. Depressive symptoms were most improved in the olanzapine-treated 'depressed' subgroup, and least improved in the corresponding haloperidol subgroup. Overall, olanzapine was superior to haloperidol with respect to thymoleptic effects in patients with Schizoaffective Disorder, bipolar type.
Leslie Citrome - One of the best experts on this subject based on the ideXlab platform.
-
Paliperidone Palmitate for Schizoaffective Disorder: A Review of the Clinical Evidence
Neurology and Therapy, 2015Co-Authors: William M. Greenberg, Leslie CitromeAbstract:Introduction Despite being frequently diagnosed, there has been very limited study of efficacious treatments for Schizoaffective Disorder. Paliperidone had been approved for the treatment of Schizoaffective Disorder, and a recently completed relapse prevention study of the use of a once-monthly injectable paliperidone formulation has also led to an indication for that preparation to treat Schizoaffective Disorder. Methods To review the efficacy and tolerability of paliperidone for Schizoaffective Disorder, we conducted a systematic literature search of studies of paliperidone in the treatment of Schizoaffective Disorder, and briefly reviewed evidence regarding the somewhat controversial nature of that diagnostic entity. Results We located several studies of the use of paliperidone extended release in the treatment of Schizoaffective Disorder, but only one completed study of the use of paliperidone palmitate, which demonstrated efficacy in preventing relapse. Three other studies are currently recruiting participants. Efficacy and tolerability were similar to the profile of oral paliperidone in the treatment of individuals with schizophrenia. These results were similar for both individuals treated with paliperidone palmitate alone, and for those treated with paliperidone palmitate with adjunctive mood stabilizers and/or antidepressants. The use of paliperidone palmitate does not require initial co-administration of oral paliperidone, has relatively little risk of drug–drug interactions, and its pharmacokinetics are favorable for once-monthly administration, an important treatment option for individuals with psychotic Disorders, who may often be non-adherent to effective medication regimens. Conclusion Paliperidone palmitate is an approved treatment for Schizoaffective Disorder, and can be efficacious with or without commonly employed adjunctive treatments.
-
Paliperidone Palmitate for Schizoaffective Disorder: A Review of the Clinical Evidence
Neurology and therapy, 2015Co-Authors: William M. Greenberg, Leslie CitromeAbstract:Introduction Despite being frequently diagnosed, there has been very limited study of efficacious treatments for Schizoaffective Disorder. Paliperidone had been approved for the treatment of Schizoaffective Disorder, and a recently completed relapse prevention study of the use of a once-monthly injectable paliperidone formulation has also led to an indication for that preparation to treat Schizoaffective Disorder.
-
Schizoaffective Disorder
CNS Drugs, 2011Co-Authors: Joshua T. Kantrowitz, Leslie CitromeAbstract:Despite a clear recognition of the existence of patients with co-morbid psychotic and mood symptoms, many studies conclude that Schizoaffective Disorder as a distinct diagnosis does not exist. Regardless of one’s opinion on Schizoaffective Disorder, psychiatrists remain dependent on phenomenological descriptions for diagnosing psychiatric Disorders, and these phenomenological criteria are also used for clinical trial entry. On the other hand, many psychiatrists prescribe for specific target symptoms and do not always rigidly follow diagnostic systems and, moreover, there have been very few trials that have specifically studied Schizoaffective Disorder. Despite recent intriguing work in epidemiology, genetics, neurocognition and electrophysiology, the diagnosis of Schizoaffective Disorder remains controversial. Taken together, these studies suggest that even if Schizoaffective Disorder exists as a separate diagnosis, it may not be useful clinically due to considerable variation in the general use of this term. It is possible that diagnostic criteria in the future will include genetic, imaging and electrophysiological components, and that this will allow for better differentiation of disease states among the heterogeneous pool of patients currently believed to have schizophrenia, Schizoaffective Disorder or bipolar Disorder. Although it is likely that most, if not all, antipsychotics are effective for Schizoaffective Disorder, given recent regulatory approval of a specific antipsychotic agent for the acute treatment of Schizoaffective Disorder, greater attention is now being focused on the entity of Schizoaffective Disorder and potential treatment decisions. However, based on the limited extant evidence, it is not yet possible to make definitive treatment recommendations for Schizoaffective Disorder. Additional clinical trials that include other antipsychotics, mood stabilizers and antidepressants are desirable and necessary before clear and comprehensive evidence-based treatment recommendations can be made.
-
Schizoaffective Disorder: a review of current research themes and pharmacological management
CNS drugs, 2011Co-Authors: Joshua T. Kantrowitz, Leslie CitromeAbstract:Despite a clear recognition of the existence of patients with co-morbid psychotic and mood symptoms, many studies conclude that Schizoaffective Disorder as a distinct diagnosis does not exist. Regardless of one's opinion on Schizoaffective Disorder, psychiatrists remain dependent on phenomenological descriptions for diagnosing psychiatric Disorders, and these phenomenological criteria are also used for clinical trial entry. On the other hand, many psychiatrists prescribe for specific target symptoms and do not always rigidly follow diagnostic systems and, moreover, there have been very few trials that have specifically studied Schizoaffective Disorder. Despite recent intriguing work in epidemiology, genetics, neurocognition and electrophysiology, the diagnosis of Schizoaffective Disorder remains controversial. Taken together, these studies suggest that even if Schizoaffective Disorder exists as a separate diagnosis, it may not be useful clinically due to considerable variation in the general use of this term. It is possible that diagnostic criteria in the future will include genetic, imaging and electrophysiological components, and that this will allow for better differentiation of disease states among the heterogeneous pool of patients currently believed to have schizophrenia, Schizoaffective Disorder or bipolar Disorder. Although it is likely that most, if not all, antipsychotics are effective for Schizoaffective Disorder, given recent regulatory approval of a specific antipsychotic agent for the acute treatment of Schizoaffective Disorder, greater attention is now being focused on the entity of Schizoaffective Disorder and potential treatment decisions. However, based on the limited extant evidence, it is not yet possible to make definitive treatment recommendations for Schizoaffective Disorder. Additional clinical trials that include other antipsychotics, mood stabilizers and antidepressants are desirable and necessary before clear and comprehensive evidence-based treatment recommendations can be made.
